tiprankstipranks
Trending News
More News >
GT Biopharma (GTBP)
NASDAQ:GTBP

GT Biopharma (GTBP) AI Stock Analysis

Compare
229 Followers

Top Page

GT

GT Biopharma

(NASDAQ:GTBP)

31Underperform
The overall score for GT Biopharma is low due to significant financial instability, as evidenced by zero revenue, continuous losses, and negative equity. Technical analysis indicates a neutral market position, but the lack of earnings and dividend yield weakens the valuation. The company's financial health and absence of positive earnings are critical concerns.

GT Biopharma (GTBP) vs. S&P 500 (SPY)

GT Biopharma Business Overview & Revenue Model

Company DescriptionGT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
How the Company Makes MoneyGT Biopharma makes money primarily through the development and commercialization of its proprietary TriKE platform, which is designed to create targeted cancer therapies. The company generates revenue through partnerships, licensing agreements, and potential future sales of its product candidates upon regulatory approval. Key revenue streams include milestone payments, royalties on sales, and collaboration agreements with larger pharmaceutical companies. Additionally, GT Biopharma may receive funding from government grants and research collaborations to support its clinical trials and research initiatives.

GT Biopharma Financial Statement Overview

Summary
GT Biopharma's financial position is precarious, with zero revenue and continuous losses indicating an urgent need for product development or strategic partnerships. The negative equity and reliance on financing highlight financial vulnerabilities, while the persistent cash outflows from operations necessitate a focus on achieving operational efficiencies or securing further investment.
Income Statement
10
Very Negative
GT Biopharma has consistently reported zero revenue over the years, indicating a lack of commercialized products. The company faces substantial operating losses, as evidenced by the negative EBIT and net income figures across all periods. This lack of revenue growth and persistent losses are significant concerns for the company's financial health.
Balance Sheet
20
Very Negative
The company has a negative stockholders' equity in recent years, indicating more liabilities than assets, which is a critical warning sign. However, the absence of debt in the latest period reduces financial risk. The low asset base and negative equity position suggest financial instability and potential solvency issues.
Cash Flow
30
Negative
GT Biopharma's operating cash flow has been consistently negative, reflecting ongoing cash burn without incoming revenue. However, the company has managed to maintain liquidity through financing activities, as seen in positive cash flow from financing. The inability to generate free cash flow further underscores the company's dependence on external funding.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
0.000.000.000.000.00
EBIT
-14.36M-13.58M-21.26M-57.52M-6.76M
EBITDA
-14.36M5.98M-20.96M-57.48M-24.98M
Net Income Common Stockholders
-13.16M-7.60M-20.50M-58.69M-31.62M
Balance SheetCash, Cash Equivalents and Short-Term Investments
3.95M13.97M16.51M31.98M5.30M
Total Assets
4.23M14.11M16.74M32.17M5.66M
Total Debt
0.0058.00K174.00K31.00K26.33M
Net Debt
-3.95M-1.02M-5.50M-8.94M21.04M
Total Liabilities
5.90M6.63M5.00M10.26M35.09M
Stockholders Equity
-1.67M7.48M11.73M21.91M-29.26M
Cash FlowFree Cash Flow
-12.90M-8.85M-15.22M-15.61M-7.26M
Operating Cash Flow
-12.90M-8.85M-15.22M-15.61M-7.26M
Investing Cash Flow
12.89M-2.01M12.14M-23.04M0.00
Financing Cash Flow
2.98M6.27M-224.00K42.32M12.53M

GT Biopharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.45
Price Trends
50DMA
2.33
Positive
100DMA
2.40
Positive
200DMA
2.45
Positive
Market Momentum
MACD
<0.01
Negative
RSI
57.95
Neutral
STOCH
45.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GTBP, the sentiment is Positive. The current price of 2.45 is above the 20-day moving average (MA) of 2.29, above the 50-day MA of 2.33, and above the 200-day MA of 2.45, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.95 is Neutral, neither overbought nor oversold. The STOCH value of 45.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GTBP.

GT Biopharma Risk Analysis

GT Biopharma disclosed 60 risk factors in its most recent earnings report. GT Biopharma reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

GT Biopharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$5.28B3.75-42.72%2.86%17.70%2.03%
42
Neutral
$7.83M-184.99%-1.54%-7.20%
APAPM
41
Neutral
$6.57M49.200.08%-100.00%
40
Underperform
$7.57M234.90%62.35%
31
Underperform
$6.14M-453.39%-26.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GTBP
GT Biopharma
2.45
-0.85
-25.76%
BCLI
Brainstorm Cell Therapeutics
1.16
-4.54
-79.65%
GNPX
Genprex
0.28
-2.16
-88.52%
APM
Aptorum Group
0.92
-4.66
-83.51%
LYRA
Lyra Therapeutics
0.11
-3.92
-97.27%
CDT
Conduit Pharmaceuticals
0.56
-299.44
-99.81%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.